Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Shares Repurchased (2020 - 2024)

Integra Lifesciences Holdings' Shares Repurchased history spans 5 years, with the latest figure at $2.5 million for Q4 2024.

  • On a quarterly basis, Shares Repurchased changed N/A to $2.5 million in Q4 2024 year-over-year; TTM through Dec 2025 was $2.5 million, a 95.29% decrease, with the full-year FY2025 number at $221000.0, down 99.58% from a year prior.
  • Shares Repurchased hit $2.5 million in Q4 2024 for Integra Lifesciences Holdings, down from $50.0 million in the prior quarter.
  • Over the last five years, Shares Repurchased for IART hit a ceiling of $150.0 million in Q1 2023 and a floor of $2.5 million in Q4 2024.
  • Historically, Shares Repurchased has averaged $92.1 million across 4 years, with a median of $112.5 million in 2020.
  • The widest YoY moves for Shares Repurchased: up 20.0% in 2023, down 20.0% in 2023.
  • Tracing IART's Shares Repurchased over 4 years: stood at $100.0 million in 2020, then increased by 25.0% to $125.0 million in 2022, then changed by 0.0% to $125.0 million in 2023, then tumbled by 98.02% to $2.5 million in 2024.
  • Business Quant data shows Shares Repurchased for IART at $2.5 million in Q4 2024, $50.0 million in Q2 2024, and $125.0 million in Q3 2023.